The exploratory analysis of the Phase III ADAURA trial, published in the Journal of Thoracic Oncology, tracked 682 participants who underwent complete surgical resection. For those with stage II-IIIA disease, the eight-year survival rate reached 74% in the osimertinib group, compared to 58% for those receiving a placebo. This translates to a hazard ratio of 0.53, highlighting the durability of the treatment effect.
In section Releases
Long-Term Survival Gains Confirmed in Eight-Year ADAURA Lung Cancer Trial
Patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer saw a significant survival advantage after eight years of adjuvant osimertinib treatment. Data presented at the 2026 World Conference on Lung Cancer confirms that early intervention with targeted therapy continues to redefine standards for long-term recovery in thoracic oncology.
Broader results across the stage IB-IIIA population mirror these findings, showing a 79% survival rate with the drug versus 64% with the placebo. Dr. Roy S. Herbst of the Dartmouth Cancer Center noted that these figures solidify the shift toward using targeted therapies in earlier disease stages to delay progression. The trial, which allowed for adjuvant chemotherapy alongside the daily 80 mg dose of osimertinib, provides evidence that three years of treatment remains the clinical benchmark for these patients.
Comments (0)
No comments yet. Be the first!